Avita Medical (ASX:AVH), a medical device company developing therapeutic solutions derived from the regenerative properties of a patient’s own skin, has announced the appointment of Erin Liberto as its Chief Commercial Officer.
Ms Liberto will have responsibility for successful execution of the company’s commercial strategy including the further development of the company’s sales, reimbursement and marketing efforts, and will report directly to CEO Dr Michael Perry.
“Erin’s extensive experience in the global dermatology markets, including a proven track record of successful US product launches, will be instrumental as we position ReCell in the US burns market following our anticipated PMA approval next year," said Dr Perry. "We are laying the foundation for our future growth across multiple indications, and I’m energized to be working with Erin as we continue to leverage our clinical progress across a broad range of indications."
Ms Liberto was most recently a vice president of marketing at Allergan.